This NDC is on FDA's drug shortage list (posted Jul 26, 2023)
Product Information
RELEXXII ER 27 MG TABLET is a brand product labeled by Vertical Pharmaceuticals, LLC, priced at $11.3247 per EA under NDC 68025009610. Its NADAC has been published 102 times since Oct 23, 2024.
FDA first approved this application on Jun 23, 2022.
The High Outlier badge above means this manufacturer's average price in the methylphenidate hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
27 mg/1
Manufacturer
Vertical Pharmaceuticals, LLCNDC
68025009610
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA216117FDA Approved
6/23/2022
On Market Since
6/23/2022
Pharmacological Classes
Price Statistics
The NADAC for RELEXXII ER 27 MG TABLET has been published 102 times since Oct 23, 2024, and over the history we have for it it has declined 2.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.3247 per EA |
|---|---|
| All-time high | $11.6437 (Jun 10, 2026) |
| All-time low | $11.3247 (Sep 23, 2026) |
| 52-week high | $11.6437 |
| 52-week low | $11.3247 |
| Median price | $11.6305 |
| Average price | $11.6047 |
| Largest weekly change | -1.4% (Jun 17, 2026) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vertical Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELEXXII ER 27 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RELEXXII ER 27 MG TABLET, manufactured by Vertical Pharmaceuticals, LLC, is $11.3247 per EA (NDC 68025009610), effective Sep 30, 2026.
How has the price of RELEXXII ER 27 MG TABLET changed over time?
Over the history we have for it, the NADAC for RELEXXII ER 27 MG TABLET has declined 2.4%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for RELEXXII ER 27 MG TABLET?
Since Oct 23, 2024, the NADAC for RELEXXII ER 27 MG TABLET has ranged from a low of $11.3247 (Sep 23, 2026) to a high of $11.6437 (Jun 10, 2026), with a median of $11.6305 per EA.
Are there cheaper alternatives to RELEXXII ER 27 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as RELEXXII ER 27 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RELEXXII ER 27 MG TABLET?
RELEXXII ER 27 MG TABLET (NDC 68025009610) is labeled by Vertical Pharmaceuticals, LLC, and CMS classifies it as a brand product.
Is RELEXXII ER 27 MG TABLET in shortage?
Yes — NDC 68025009610 is currently listed in FDA's drug shortage database (posted Jul 26, 2023).